| http://www.w3.org/ns/prov#value | - Generics will be the best performing segment, posting a 9.25% CAGR to 2020.The above outlook is supported by development such as the announcement that the Malaysian government is looking to raise quality and technical standards in the local pharmaceutical industry by tightening bioequivalence rules.
|
